MedTrace Logo

The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

NCT00674453 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2011-08-10

No results posted yet for this study

Summary

The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.

Conditions

  • Bone Loss

Interventions

DRUG

Lasofoxifene

Oral tablet, 0.25 mg, daily, 2 years

OTHER

Placebo

Matching placebo tablet given once daily for 2 years

Sponsors & Collaborators

  • Ligand Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2007-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674453 on ClinicalTrials.gov